Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: ALEC alector.com
Alector is a biotechnology company focused on developing therapies to counteract the progression of neurodegenerative diseases. Leveraging principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of preclinical programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Its pipeline targets indications including Alzheimer's disease and Parkinson's disease. Central to its strategy is the proprietary Alector Brain Carrier (ABC) blood-brain barrier platform, designed to enhance therapeutic delivery to the brain across multiple drug modalities including antibodies, enzymes, and siRNA. The company's lead program, AL137, is an ABC-enabled anti-amyloid beta antibody for Alzheimer's disease targeting IND submission in early 2027. Additional programs include AL064/AL164 (tau siRNA for Alzheimer's and tauopathies) and AL050 (GCase enzyme replacement therapy for Parkinson's disease). Alector has no marketed products and generates revenue from collaboration agreements. The company trades on Nasdaq under the ticker ALEC. Updated
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each. Hims & Hers Health (NYSE:HIMS) received two separate upgrades after…
Alector is a biotechnology company focused on developing therapies to counteract the progression of neurodegenerative diseases.
The Wall Street consensus 12-month price target for ALEC is $3.30.
